Fundraising Fox
BrainSpec
Techstars '17Boston, US · Founded 2015 · Delaware corporation · 16 employees on LinkedIn · 4 known investors
Find your way into BrainSpec
Sign up to see every warm intro you have to BrainSpec
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BrainSpec team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BrainSpec develops software for analyzing and visualizing MR spectroscopy (MRS) neuroimaging data, aiming to make a non-invasive "virtual biopsy" available to clinicians and researchers. Its technology targets patient populations with conditions such as brain tumors, Alzheimer's disease, and Multiple Sclerosis.
Also known as BrainSpec Core
Founders & leadership
Investors · 4
How we know: Bacchus Venture Capital's portfolio page · Not right? Tell us
How we know: DCVC (Data Collective)'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$1.7M disclosed across 1 round · 2017
▶$1.7MraisedSep 2017 · 6 investors · Other TechnologyRule 506(b)
- Alexandra ZimmermanExecutive Officer, Director
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Sep 2026BrainSpec develops a cloud-based software platform for magnetic resonance spectroscopy (MRS), a technique that measures the concentration of chemical metabolites in tissue using standard MRI hardware rather than producing an anatomical image. The company positions MRS analysis as a 'virtual biopsy': a way to characterize brain tissue composition and metabolism without a surgical procedure and without ionizing radiation. Its product, BrainSpec Core, pairs a post-processing backend built on a linear-combination model with a browser-based interface intended for use by both clinicians and researchers, and supports precision metabolite measurement, cross-vendor data support and automatic report generation.
The platform targets neurometabolites including N-acetylaspartate, choline, creatine, glutamate, glutamine, myo-inositol, lactate and 2-hydroxyglutarate, which are used as markers of neuronal health, cell membrane turnover, energy metabolism, neurotransmission, cellular stress and tumor activity. Stated clinical and research applications span brain tumors, Alzheimer's disease and multiple sclerosis, among other neurological conditions. Alongside the analysis software, BrainSpec is building a reference database of normal brain chemistry for clinical use and a broader database of diseased brain chemistry for research, with the goal of making MRS results interpretable in a manner comparable to routine blood test results.
Founding story
The founding team came together at a brainstorming session hosted by the iHub at Brigham and Women's Hospital, an initiative intended to help clinicians and researchers develop their ideas into products. The company was founded in 2015 by Alexandra Zimmerman together with co-founder Alexander P. Lin, Ph.D., director of the Center for Clinical Spectroscopy in the Department of Radiology at Brigham and Women's Hospital and associate professor of radiology at Harvard Medical School. Additional collaborators include radiologists, oncologists, neurologists and neurosurgeons at Brigham and Women's Hospital and Massachusetts General Hospital.
Business model
BrainSpec supplies software rather than imaging hardware, running analysis of customer-acquired MRS data through a cloud platform used by hospitals, clinicians and research groups.
Traction
BrainSpec Core is pending FDA clearance and is offered for research use only, with a limited number of pilot research sites being accepted as of the company's 2024 site. The company reported an AI software milestone in generating brain-chemical measurements from MRS data in December 2023 coverage.
Latest developments
As of December 2023, BrainSpec's software was reported to have reached a milestone in producing brain-chemical measurements from non-invasive MRS scans, and the company was pursuing FDA clearance; its 2024 website indicates BrainSpec Core remains pending clearance and open to a limited set of research pilot sites.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
BrainSpec states it aims to be the first AI software platform using brain-chemistry data to receive FDA clearance. Its co-founder frames the approach as complementary to, rather than competing with, existing AI and digital-health tools in brain imaging, which focus largely on structural changes, whereas MRS addresses underlying pathophysiological chemistry.
The platform combines a quantitative linear-combinations post-processing backend with a non-specialist web interface, cross-vendor data handling and automated reporting, and is paired with reference databases of normal and diseased brain chemistry intended to make MRS interpretation routine. It relies on MRS sequences obtainable from standard MRI scanners, so no dedicated equipment is required.
Technology
The core technology is a web-based MRS post-processing and visualization platform. Spectroscopy data acquired as an additional sequence on standard MRI scanners is processed in the cloud using a linear-combinations model to quantify metabolite concentrations, with results delivered through a browser interface and automated reports. The company describes support for data from multiple scanner vendors and cloud processing so that analyses reflect the latest version of its methods. Press coverage characterizes the product as an AI/machine-learning software platform that derives brain-chemistry measurements from non-invasive MRS scans. MRS detects metabolites at concentrations roughly 10,000 times lower than those measured by conventional MRI, producing a frequency-domain readout of resonances in parts per million rather than an image.
Go-to-market
The company markets directly to clinicians and researchers through its website, offering product demos, a waitlist for new use cases and a feedback channel. It is accepting a limited number of pilot sites for research use while BrainSpec Core remains pending FDA clearance, and maintains research-site relationships alongside collaborators at Brigham and Women's Hospital and Massachusetts General Hospital.
Radiologists, oncologists, neurologists, neurosurgeons and other clinicians in hospitals with standard MRI equipment, plus academic and industry neuroimaging researchers working on brain tumors, neurodegenerative disease and other neurological conditions.
Geography
Headquartered in Boston, with research sites listed by the company and clinical collaborators at Brigham and Women's Hospital and Massachusetts General Hospital.
Risks & controversies
BrainSpec Core has not received FDA clearance and is labeled for research use only, so clinical commercialization depends on a pending regulatory decision.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsThe company states that BrainSpec Core is pending FDA clearance and is available for research use only, with a limited number of pilot sites being accepted.
Press coverage reported that BrainSpec's AI software reached a milestone in using data from non-invasive magnetic resonance spectroscopy scans to provide measurements of brain chemicals, and that the company aims to be the first AI platform using brain-chemistry data cleared by the FDA.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 8
primary sources listed
- BrainSpecbrainspecmed.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does BrainSpec do?
- BrainSpec builds a web-based platform that analyzes MR spectroscopy scans to deliver a non-invasive 'virtual biopsy' of brain chemistry.
- Who are BrainSpec's investors?
- BrainSpec's investors include Bacchus Venture Capital, DCVC (Data Collective), Dorm Room, Techstars.
- How much funding has BrainSpec raised?
- BrainSpec has disclosed $1.7M raised across 1 round.
- Where is BrainSpec headquartered?
- BrainSpec is headquartered in Boston, US.